Contextualising evidence based medicine in determining the key root for translational effectiveness for chronic disease self-management and heart failure

Abstract

Background: Congestive heart failure (CHF) management has proven devastating on morbidity, mortality, quality of life and also costly to health systems. Therapeutics for CHF have advanced and benefited greatly due to large multicentre randomised controlled trials and the evidence obtained from them. Management for chronic diseases and nonpharmaceutical therapies such as chronic disease selfmanagement has lagged, and for CHF the evidence base has even been questioned. Methods: Perspective and non systematic mini review. Conclusions: Advancing translational research standards is important to achieve optimal cost effectiveness. Importantly is understanding evidence generation in medicine, identifying the primary roots for management and its translation.

Prognostic value of serum IGF-1, Gal-3, and PTX-3 levels in elderly patients with chronic heart failure

“…These collectively result in ventricular dysfunction and play a significant role in the occurrence and development of heart failure [17]. Studies have shown that Gal-3, as a new biomarker, is involved in the regulation of cardiac fibrosis and ventricular remodeling, and its abnormally high expression contributes to left ventricular remodeling in chronic heart failure [18]. Research [19] has shown that Gal-3 in patients with NYHA grade II, III and IV was remarkably higher than that in healthy subjects, its level in NYHA patients with good prognosis was notably lower than those with poor prognosis, and Gal-3 was negatively correlated with LVEF and positively correlated with LVEDD.…”

Heart Failure Paradigms in the Developed World – A ‘Taproot’ Plan (Part 2)

“…In a recent publication, we highlighted the concept of the taproot. In this system, addressing the issues in critical areas can contain or prevent an escalation of issues to epidemic proportions [ 2 ]. Health care costs are escalating.…”